UNSPSC 51162018: Dextromethorphan/dyphylline/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162018 Dextromethorphan/dyphylline/pseudoephedrine is a Commodity code that in practice covers a broader range of pharmaceutical procurement than its nominal scope suggests. State and local governments soliciting under this code are actually buying naloxone and drug deactivation systems, on-site pharmacy services, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription fulfillment arrangements. The issuing bodies span county health departments (Seminole County, Florida; Hall County, Georgia), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and other participating jurisdictions). The mix reflects both acute-care and preventive-health needs — naloxone procurement for opioid emergencies, employer-group pharmacy services for county employees and retirees, and systemic generic-drug supply agreements serving government facilities statewide and across regions.

Recent activity appears concentrated in the South and Midwest, with posted opportunities in Florida, Georgia, Texas, and Minnesota as of early 2026. Representative solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) seeking 1,900 annual units of naloxone and 800 drug deactivation systems through quarterly deliveries; Hall County's RFQ/P #47-010 (posted May 4, 2026, due June 4, 2026) for on-site pharmacy services to 3,005 eligible individuals; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026), which supplies authorized wholesalers across multiple states with awarded vendors effective July 1, 2026. The code shows ongoing state and local demand for pharmaceutical supply chain solutions across emergency response, employer health benefits, and bulk procurement models.